ATE419370T1 - Lentivirale vektoren zur behandlung von schmerzen - Google Patents

Lentivirale vektoren zur behandlung von schmerzen

Info

Publication number
ATE419370T1
ATE419370T1 AT02758603T AT02758603T ATE419370T1 AT E419370 T1 ATE419370 T1 AT E419370T1 AT 02758603 T AT02758603 T AT 02758603T AT 02758603 T AT02758603 T AT 02758603T AT E419370 T1 ATE419370 T1 AT E419370T1
Authority
AT
Austria
Prior art keywords
eoi
lentiviral vectors
treating pain
delivering
target cell
Prior art date
Application number
AT02758603T
Other languages
English (en)
Inventor
Rob Barber
Mimoun Azzouz
Nick Mazarakis
Susan Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122237A external-priority patent/GB0122237D0/en
Priority claimed from GB0210575A external-priority patent/GB0210575D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE419370T1 publication Critical patent/ATE419370T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Electrotherapy Devices (AREA)
AT02758603T 2001-09-14 2002-09-12 Lentivirale vektoren zur behandlung von schmerzen ATE419370T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0122237A GB0122237D0 (en) 2001-09-14 2001-09-14 Vector system
GB0210575A GB0210575D0 (en) 2002-05-08 2002-05-08 Vector system

Publications (1)

Publication Number Publication Date
ATE419370T1 true ATE419370T1 (de) 2009-01-15

Family

ID=26246544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758603T ATE419370T1 (de) 2001-09-14 2002-09-12 Lentivirale vektoren zur behandlung von schmerzen

Country Status (5)

Country Link
US (2) US20040170608A1 (de)
EP (1) EP1425403B1 (de)
AT (1) ATE419370T1 (de)
DE (1) DE60230641D1 (de)
WO (1) WO2003025188A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495398A1 (en) * 2002-08-14 2004-02-26 Pharmacia Corporation Antisense modulation of nav1.3 expression
WO2004073646A2 (en) * 2003-02-19 2004-09-02 University Of Rochester Treatment of pain through expression of opioid receptors
EP1883427A4 (de) 2005-01-20 2010-04-21 Univ Rochester Zusammensetzungen und verfahren zur untersuchung und behandlung von entzündlichen krankheiten und erkrankungen
WO2007087580A2 (en) * 2006-01-24 2007-08-02 The University Of Chicago Y134.5 deficient hsv comprising a coding region of a member of the mapk pathway for the treatment of a cell proliferation disorder
US8435762B2 (en) * 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010074493A (ko) * 1998-05-22 2001-08-04 찰스 굿맨 레트로바이러스 전달 시스템
WO2000018903A2 (en) * 1998-09-29 2000-04-06 The Johns Hopkins University Inducible genetic suppression of cellular excitability
US6677332B1 (en) * 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6221600B1 (en) * 1999-10-08 2001-04-24 Board Of Regents, The University Of Texas System Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis
JP2004517057A (ja) * 2000-11-03 2004-06-10 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム

Also Published As

Publication number Publication date
US20040170608A1 (en) 2004-09-02
US20070041947A1 (en) 2007-02-22
DE60230641D1 (de) 2009-02-12
EP1425403B1 (de) 2008-12-31
WO2003025188A1 (en) 2003-03-27
EP1425403A1 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60231907D1 (de) Vorrichtung zur mehrstellenbehandlung von tachykardien
WO2003045316A3 (en) Polynucleotide therapy
ATE286392T1 (de) Photodynamische behandlung von synovium
MY151032A (en) Treatment of tnf? related disorders
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
BRPI0211200B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DE60230807D1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
BR0209990A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
WO2005089426A3 (en) Method of treating sepsis
DE60230641D1 (de) Lentivirale vektoren zur behandlung von schmerzen
ATE304365T1 (de) Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
EA199800821A1 (ru) Способ лечения аутизма

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties